Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report details a specific share repurchase transaction executed on May 8, 2012, following shareholder authorization granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure and share repurchase activity.
- Shares Repurchased: 1,700,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,448 pence per share; lowest price paid was 1,425 pence per share.
- Treasury Holdings (Settled): 520,997,927 shares (9.36% of total issued share capital).
- Treasury Holdings (Including Unsettled): 525,297,927 shares (10.42% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,043,394,822 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,700,000 shares. Consequently, the percentage of shares held in Treasury increased to 10.42% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share buybacks.
Investor Verification Checklist
- Verify the total cost of the 1,700,000 share repurchase based on the weighted average price between 1,425 and 1,448 pence.
- Confirm the impact of the 10.42% Treasury holding on the denominator for shareholder notification thresholds under Disclosure and Transparency Rules.
- Check subsequent filings to confirm the settlement of the 4,300,000 shares currently held in Treasury but not yet settled.